New GLP-1 diabetes pill delivers major weight loss and blood sugar control
A phase 2b clinical trial for the experimental oral drug elecoglipron showed significant improvements in blood sugar control and weight loss for type 2 diabetes patients. The study suggests that non-peptide oral GLP-1 agonists could offer a more convenient alternative to current injectable treatments.
Why it matters
Advancements in oral GLP-1 medications could drastically improve patient compliance and accessibility for millions living with type 2 diabetes.
A new experimental GLP-1 pill could make it easier for people with type 2 diabetes to access treatments that help control blood sugar and support weight loss.
The article summarizes scientific findings from a clinical trial published in a peer-reviewed journal.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in